Synopsis: A pharma stock rallied more than 17 percent after reporting a strong Q1 performance, but the sharp market reaction wasn’t driven by profit growth alone. The company delivered broad-based strength across its core businesses, expanded margins, reduced finance costs, and reaffirmed an optimistic FY27 outlook, signalling that its long-term growth strategy may be gathering momentum.
Strong quarterly results often go beyond headline revenue and profit numbers. They reveal whether a company’s growth is sustainable, margins are improving, and future earnings visibility is strengthening. Reflecting this, Beta Drugs Ltd. reported a robust Q1 FY27 performance, with healthy growth across branded oncology, contract manufacturing, exports, and consumer healthcare, while management reiterated its confidence in delivering 20–25 percent consolidated growth during FY27.
Shares of Beta Drugs Limited were trading at Rs 2,613, up by 17.16 percent from the previous close of Rs 2,229.1. The stock opened at Rs 2,299.0, touching an intraday high of Rs 2,620 and a low of Rs 2,299. The company currently has a market capitalisation of Rs 2,562 crore.
Financial Performance
Beta Drugs reported consolidated revenue from operations of Rs 125.55 crore during Q1 FY27, registering a year-on-year growth of 25.3 percent from Rs 100.20 crore in the corresponding quarter of the previous year. Including other income, total revenue stood at Rs 127.13 crore, reflecting continued business momentum across domestic and international markets.
The earnings performance was even more impressive. Profit Before Tax (PBT) increased by nearly 41 percent to Rs 22.04 crore, while Profit After Tax (PAT) rose to Rs 16.49 crore, compared with Rs 11.70 crore in Q1 FY26. Earnings per share (EPS) also improved from Rs 11.59 to Rs 14.78, highlighting stronger earnings generation for shareholders.
More importantly, profit grew significantly faster than revenue, indicating that the company wasn’t merely selling more products but was also improving the quality of its earnings through a better business mix, higher margins, and disciplined cost management.
Finance costs fell sharply, helping the quarter’s profitability. Interest expenses for Compulsorily Convertible Debentures (CCDs) decreased to Rs 0.75 crore in Q1 FY27 from Rs 2.10 crore in the same quarter last year after their conversion in May 2026. The lower financing burden allowed more operating profits to flow to the bottom line, improving earnings quality.
Key Business Highlights
Growth during the quarter was broad-based, with every major business vertical contributing positively. The Branded Oncology segment remained the biggest growth driver, delivering 47 percent year-on-year growth to Rs 33 crore, supported by improved demand for existing products and increasing acceptance of new launches made last year.
The Contract Manufacturing Organisation (CMO) business registered 41 percent growth, driven by strong customer traction and the commercialisation of proprietary NDDS (Novel Drug Delivery System) products. Management expects better realisations from platinum-based products to further support this business in FY27. Exports contributed Rs 17.2 crore during the quarter, with order inflows accelerating and expected to drive stronger growth in the remaining quarters of the year.
Meanwhile, Nivian Lifesciences delivered 45 percent year-on-year growth, benefiting from deeper market penetration and the full-quarter contribution of products launched in the previous quarter. Management also expects operational synergies between Beta Drugs and Nivian to improve profitability going forward.
The company also reported meaningful improvement in operating profitability. EBITDA (excluding other income) increased by 38.9 percent to Rs 27.37 crore, while EBITDA margins improved to 21.8 percent.
Including other income, EBITDA stood at Rs 28.95 crore, translating into a margin of 23.06 percent. Gross margins expanded sharply from 50.4 percent in Q1 FY26 to 56.6 percent, driven by a favourable shift towards higher-margin branded oncology products and Nivian’s consumer healthcare portfolio. Management believes this favourable business mix will continue to support margin expansion in the coming years.
Management Outlook
Management reiterated its Vision 2030, aiming to become a leading formulations company with more than 50 percent of revenue generated from its own branded products, while branded products and exports together are expected to contribute over 80 percent of total turnover by 2030.
For FY27, the company continues to guide for 20–25 percent consolidated revenue growth. It also expects backward integration into Key Starting Materials (KSMs) and advanced intermediates to improve operating margins further.
Alongside this, Beta Drugs plans to continue investing in research and development, expand its pipeline of NDDS products, and focus on launching differentiated oncology therapies to strengthen its position in both domestic and international markets.
Overall, Beta Drugs’ Q1 performance reflects more than just higher revenue and profits. The quarter demonstrated improving business quality through stronger branded sales, better margins, lower finance costs, accelerating exports, and multiple growth engines contributing simultaneously.
The results suggest that Beta Drugs Limited is building a stronger platform for sustainable and profitable growth, supported by management’s long-term strategy focused on innovation, branded products, and backward integration.
Beta Drugs Limited is an oncology-focused pharmaceutical company engaged in the development, manufacturing, and marketing of anti-cancer formulations. The company operates across branded oncology, contract manufacturing, exports, and consumer healthcare through Nivian Lifesciences while continuing to invest in research, NDDS technologies, and differentiated oncology products for domestic and international markets.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
